Physician profile
Bertha Baum
NPI 1801162094
$297,962.54
in general payments reported to CMS, 2019-2025
46 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $4,620 · 2021: $60K · 2022: $46K · 2023: $100K · 2024: $36K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174K · Food and Beverage: $7,787 · Travel and Lodging: $3,350 · Consulting Fee: $350 · Education: $68.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,904.08 |
| Food and Beverage | $7,786.70 |
| Travel and Lodging | $3,350.08 |
| Consulting Fee | $350.00 |
| Education | $68.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $187,684.87 | 2019-2025 | Nemluvio, Dysport |
| Abbvie INC. | $99,272.48 | 2019-2025 | Botox, Kybella, Rinvoq |
| Pfizer INC. | $977.31 | 2021-2025 | |
| Allergan, INC. | $972.66 | 2019-2022 | |
| Genzyme Corporation | $741.42 | 2019-2025 | |
| Merz North America, INC. | $694.57 | 2019-2025 | Xeomin |
| Incyte Corporation | $662.76 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $653.89 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $639.56 | 2019-2023 | Absorica Ld, Winlevi, Ilumya |
| Vyne Pharmaceuticals INC. | $562.69 | 2020-2021 | |
| Journey Medical Corporation | $534.12 | 2019-2023 | |
| Almirall LLC | $519.53 | 2019-2025 | Seysara, Klisyri |
| Janssen Biotech, INC. | $431.69 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $404.99 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $350.67 | 2019-2023 | Altreno, Retin-A, Siliq |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bertha Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.